CoChat

Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer.

Bardia, Aditya, Modi, Shanu, Chavez-Mac Gregor, Mariana, Kittaneh, Muaiad, Marino, Alyssa J., Matano, Alessandro, Bhansali, Suraj, Hewes, Becker, Cortes, Javier · 2014 · Journal of Clinical Oncology
Cited by 23

The DOI matches its Crossref record.

Abstract

535 Background: Aromatase inhibitors (AIs) are the recommended first-line endocrine therapy for postmenopausal (PM) patients (pts) with ER+/HER2– advanced/metastatic breast cancer (aBC). However, resistance develops over time. Activation of the PI3K/AKT/mTOR pathway and downstream cyclin D–cyclin-dependent kinase (CDK4/6) has been implicated in endocrine-therapy resistance. Combination of the mTOR inhibitor everolimus (EVE) with exemestane (EXE) significantly improved PFS of pts with ER+/HER2– aBC (BOLERO-2), and preclinical data suggest that combination of EXE, EVE, and the CDK4/6 inhibitor LEE011 may be even more effective in endocrine-resistant ER+/HER2– BC. Methods: During Phase (Ph) Ib, PM pts with ER+/HER2– aBC are being treated with escalating doses of LEE011 (3 wks on/1 wk off), EVE (continuous), and a fixed daily dose of EXE (25 mg/d; continuous; arm 1); or with a safety run-in of LEE011 (600 mg/d; 3 wks on/1 wk off) and EXE (25 mg/d; continuous; arm 2) to confirm the recommended Ph II dose (RP2D). The primary objective of the Ph Ib part of the study is to determine the maximum tolerated dose and/or RP2D in arm 1. Safety, tolerability, and PK will also be assessed. Dose escalation is guided by a Bayesian Logistic Regression Model (BLRM) with overdose control principle. Results: As of Dec 12, 2013, 6 pts have been treated in arm 1 with 200 mg/d LEE011, 2.5 mg/d EVE, and EXE, and among the 5 pts evaluable for dose determination, no DLTs were observed. AEs observed to date have been mainly hematologic (as expected with a CDK 4/6 inhibitor) and mild to moderate.Preliminary PK suggest that LEE011 exposure in the presence of EVE is similar to that of single agent, while for EVE there was a 2-fold increase in exposure at steady state.Pts are currently being treated in arm 1 cohort 2 (300 mg/d LEE011, 2.5 mg/d EVE, and EXE) and in arm 2. Conclusions: To the best of our knowledge, this is the first trial evaluating an AI in combination with an mTOR and a CDK4/6 inhibitor. Preliminary data suggest that the triple combination of LEE011 + EVE + EXE is feasible. The exposure of EVE is slightly increased. In Ph II of the study, pts will be randomized to receive LEE011 + EVE + EXE, LEE011 + EXE, or EVE + EXE, and safety and efficacy compared. Clinical trial information: NCT01857193.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.535

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 23

Metadata

Authors
Bardia, A., Modi, S., Chavez-Mac Gregor, M., Kittaneh, M., Marino, A. J., Matano, A., Bhansali, S., Hewes, B., & Cortes, J.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
535-535
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2529242108
Cited by
23
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.535
The paper
Bardia, A., Modi, S., Chavez-Mac Gregor, M., Kittaneh, M., Marino, A. J., Matano, A., Bhansali, S., Hewes, B., & Cortes, J. (2014). Phase Ib/II study of LEE011, everolimus, and exemestane in postmenopausal women with ER+/HER2-metastatic breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.535

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.